Plain-English translation of NCT06258668 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study of how Sotyktu () performs in Korean patients with moderate-to-severe plaque psoriasis. Rather than running a controlled laboratory experiment, researchers will follow people who are already taking this medication as prescribed by their doctors, and collect information about how well it works and how safe it is. The goal is to understand this treatment's benefits and any side effects in everyday clinical practice.
While this medication has been tested before approval, companies are required to continue watching how it performs once it's available to patients in the real world. This study helps make sure the medication is working as expected and is safe for the Korean population who use it.
You likely qualify if…
You likely don't qualify if…
You will continue taking your psoriasis medication as your doctor prescribed. Researchers will collect information from your medical records about how the treatment is working, your skin improvement, and any side effects you experience. This is a follow-up study, not a new treatment trial, so you receive the medication through your normal medical care rather than as part of a research protocol.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
South Korea
Sponsor
Bristol-Myers Squibb
Enrollment target
~505 participants
Started
August 2024
Primary completion
September 2028
Age range
19 Years and older
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
BMS Study Connect Contact Center www.BMSStudyConnect.com
Bristol-Myers Squibb
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.